EP2531203A2 - Huile essentielle de mentha suaveolens et ses activités thérapeutiques - Google Patents

Huile essentielle de mentha suaveolens et ses activités thérapeutiques

Info

Publication number
EP2531203A2
EP2531203A2 EP11709470A EP11709470A EP2531203A2 EP 2531203 A2 EP2531203 A2 EP 2531203A2 EP 11709470 A EP11709470 A EP 11709470A EP 11709470 A EP11709470 A EP 11709470A EP 2531203 A2 EP2531203 A2 EP 2531203A2
Authority
EP
European Patent Office
Prior art keywords
oil
mentha suaveolens
essential oil
mentha
antifungal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP11709470A
Other languages
German (de)
English (en)
Inventor
Letizia Angiolella
Rino Ragno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita degli Studi di Roma La Sapienza
Original Assignee
Universita degli Studi di Roma La Sapienza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita degli Studi di Roma La Sapienza filed Critical Universita degli Studi di Roma La Sapienza
Publication of EP2531203A2 publication Critical patent/EP2531203A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present description refers to an essential oil of Mentha suaveolens; in particular, described herein is an oil containing at least 60% of piperitenone oxide, at least 0.5% of alpha-cubebene and at least 0.5% of octanol, its use as medicament, compositions and products containing it.
  • Essential oils are extracted from various aromatic plants, generally located in temperate-hot countries, such as Mediterranean ones, and tropical countries where they represent a relevant part of traditional Pharmacopeia.
  • Essential oils are very complex natural mixtures which may contain about 20-60 components with very different concentrations according to the plant type from which they are extracted, but also according to the time period in which the plant material used for the extraction is harvested.
  • Melaleuca alternifolia is an Australian myrtacea from whose leaves the oily essence is obtained.
  • the leaves subjected to steam current extraction, yield the essential oil, also referred to as TEA TREE OI L, having an activity reported as germicidal, bactericidal, fungicidal; said oil is used in aromatherapy as anti- infective, cicatrizing, antiseptic agent; it is used for the treatment of chronic cystites of colibacillar origin, vaginal infections from Candida, skin infections, it is useful for the treatment of infections from C. albicans, E. coli, S. aureus, P.
  • oils are those of plants of genus Mentha (family Lamiaceae).
  • the constituents of essential oils obtained from species of genus Mentha are very heterogeneous and can vary within the range of the same species, giving origin to essences different by chemistry, pharmacology and toxicology.
  • the most studied species are Mentha spicata (green mint) and Mentha piperita (peppermint) which, though belonging to th e sa me gen u s, produce essential oils of different composition, each with peculiar therapeutic properties (Lupien et al, 1999; McConkey et al, 2000).
  • an essential oil extracted from species Mentha suaveolens having antibacterial and antifungal properties. This oil owes its properties to the peculiar composition.
  • pulegone is the component indicated as responsible for the inhibition activity that such oil exerts on the growth of the various microorganisms, and therefore for the antibacterial and antifungal activity observed (Oumzil H . et all., 2002).
  • TTO essential oils capable of providing extremely effective antifungal and/or antibacterial effects
  • TTO substances of natural origin sometimes have, in association to undoubtedly effective medical effects, other effects or features that may limit their use; in the case of TTO, the negative effect of greater relevance is the extremely unpleasant, pungent and persistent odor of said substance, inhibiting a topical use thereof by the patient, who should spread such a foul-smelling substance on various parts of his/her body.
  • TTO the negative effect of greater relevance is the extremely unpleasant, pungent and persistent odor of said substance, inhibiting a topical use thereof by the patient, who should spread such a foul-smelling substance on various parts of his/her body.
  • This oil having a negligible percentage of pulegone, surprisingly exhibits therapeutic activities, such as activities of inhibition of the growth of various microorganisms at concentrations lower than those defined for the other essential oils known in the literature.
  • Mentha suaveolens containing at least 60% of piperitenone oxide, at least 0.5% of alpha-cubebene and at least 0.5% of octanol;
  • the essential oil extracted from plant material of Mentha suaveolens has a peculiar composition, with a negligible concentration of pulegone, which from what is known in the literature did not forecast the effective antifungal and/or antibacterial and/or antiviral abilities thereof.
  • oil of th e present i nvention could have a composition as that reported in Table 1 .
  • Mentha suaveolens oil with a percentage of piperitenone oxide of at least 60% may be used as medicament.
  • object of the description is a Mentha suaveolens oil having a percentage of piperitenone oxide of at least 60%, of at least 0.5% of alpha- cubebene and of at least 0.5% of octanol as medicament.
  • the oil disclosed herein may be used as antibacterial under conditions in which an action of inhibiting or slowing down the growth of bacterial microorganisms is desired.
  • Said antibacterial action could be exerted against bacteria belonging to the families Staphylococcus spp, Streptococcus spp and Escherichia coli spp, like e.g. bacteria selected in the group comprising S. aureus, S. piogens, S. agalactiae.
  • Such effects are exerted at a min imu m inh ibitory concentration (MIC) and at a minimum fungicidal concentration (MFC) lower than that of TTO in comparative experiments (see Table 2).
  • MIC min imu m inh ibitory concentration
  • MFC minimum fungicidal concentration
  • Such antifungal activity is observed also toward strains resistant to drugs commonly used against infections from fungi.
  • said drugs may be azolic drugs. Therefore, said oil may be used in the treatment of fungal infections not responding to drugs commonly used against said infections. I n a particular embodiment such drugs can be the azolic drugs, like e.g. fluconazole.
  • the authors of the present invention have detected how the above-mentioned oil exerts an antiviral activity against herpes simplex Virus type-1 and type-2 (HSV-1 and HSV-2) which is of particular interest for the applications of the oil of the invention indicated herein.
  • the compound of the present invention is typically formulated in forms of pharmaceutical dosage, to give an easily controllable drug dosage and allow patient compliance with the prescribed regimen.
  • composition according to the present description is preferably sterile.
  • the formulations to be used for an in vivo administration should be sterile. Such sterilization is easily carried out, e.g., by filtering through suitable sterile membranes.
  • the oil could be used in such compositions as sole active principle, or even in combination with one or more biologically active substances.
  • such compositions will comprise at least 1 .5% of sai d oi l , optionally mixed with pharmaceutically acceptable diluents, vehicles, exci pients or stabi l izers (Remington's Pharmaceutical Sciences (1980) 16th edition, Osol, A. Ed.).
  • compositions could be suitable for rectal , topical, vaginal administration, for administration by inhalation or nasal administration to a mammal such as a human being.
  • Suppository formulations may be prepared by mixing the active ingredient with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal and/or vaginal temperature, and therefore will dissolve in the rectum or vagina to release the drug.
  • suitable excipients include, e.g., cocoa butter and polyethylene glycols.
  • Formulations suitable for vaginal administration could be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing, beside the active ingredient, those vehicles known as suitable in the state of the art.
  • said oil has a valid use at a dose of at least 10-15 drops of pure oil by inhalatory route, twice per day.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention a pour objet une huile essentielle de Mentha suaveolens ; la présente invention concerne en particulier une huile contenant au moins 60 % d'oxyde de pipériténone, au moins 0,5 % d'alpha-cubébène et au moins 0,5 % d'octanol, son utilisation en tant que médicament, des compositions et des produits la contenant.
EP11709470A 2010-02-01 2011-01-28 Huile essentielle de mentha suaveolens et ses activités thérapeutiques Ceased EP2531203A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2010A000035A IT1398185B1 (it) 2010-02-01 2010-02-01 Olio essenziale di mentha suaveolens e sue proprieta' medicamentose.
PCT/IB2011/050386 WO2011092655A2 (fr) 2010-02-01 2011-01-28 Huile essentielle de mentha suaveolens et ses activités thérapeutiques

Publications (1)

Publication Number Publication Date
EP2531203A2 true EP2531203A2 (fr) 2012-12-12

Family

ID=42342894

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11709470A Ceased EP2531203A2 (fr) 2010-02-01 2011-01-28 Huile essentielle de mentha suaveolens et ses activités thérapeutiques

Country Status (3)

Country Link
EP (1) EP2531203A2 (fr)
IT (1) IT1398185B1 (fr)
WO (1) WO2011092655A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112423771B (zh) * 2018-07-20 2023-05-09 株式会社资生堂 病毒灭活剂
CN109985031A (zh) * 2019-03-21 2019-07-09 新疆医科大学 长叶薄荷酮在制备抑制大肠杆菌生物膜形成的药物的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3828163B2 (ja) * 1994-06-10 2006-10-04 サンスター株式会社 抗炎症、抗かゆみ剤
JP2003321488A (ja) * 2002-04-24 2003-11-11 Hajime Ikegai 抗菌性抽出物及びその製造方法並びに抗菌剤組成物
KR101336726B1 (ko) * 2007-02-28 2013-12-04 주식회사 엘지생활건강 식물의 꽃 절편을 포함하는 치약 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Mint. The Genus Mentha", 1 January 2006, CRC PRESS, ISBN: 978-0-84-930779-9, article BRIAN M LAWRENCE: "CHAPTER 8: Oil Composition of Other Mentha Species and Hybrids", pages: 325 - 346, XP055171420 *
See also references of WO2011092655A2 *

Also Published As

Publication number Publication date
ITRM20100035A1 (it) 2011-08-02
IT1398185B1 (it) 2013-02-14
WO2011092655A2 (fr) 2011-08-04
WO2011092655A3 (fr) 2011-11-10

Similar Documents

Publication Publication Date Title
Sabandar et al. Medicinal property, phytochemistry and pharmacology of several Jatropha species (Euphorbiaceae): a review
ES2873449T3 (es) Composición rica en hidroxitirosol a partir de agua de vegetación de aceitunas y método de uso del mismo
Castro Propolis: biological and pharmacological activities. Therapeutic uses of this bee-product
US20090191288A1 (en) Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
US20080057136A1 (en) Disinfecting Composition and Methods of Making and Using Same
ES2726052T3 (es) Composiciones que contienen ácido pirrolidona carboxílico (pca) y sales metálicas
JP5551848B2 (ja) 痒み防止皮膚外用剤
Ogungbe et al. Phytochemical investigation of Verbesina turbacensis Kunth: Trypanosome cysteine protease inhibition by (–)-bornyl esters
US20160151436A1 (en) Treatment of Herpes, Pseudomonas, Staph, and Hepatitis
US20200179473A1 (en) Anti-pathogenic compositions
Kumari et al. Promising essential oils/plant extracts in the prevention and treatment of dandruff pathogenesis
WO2008072988A1 (fr) Compositions à base de miel de consistance telle qu'elles peuvent être délivrées au système respiratoire
CN104815096B (zh) 一种纳米复合皮肤消毒乳液及其制备方法
Patarca et al. Effects of benzalkonium salts on eukaryotic and microbial G-protein-mediated processes and surface membranes
WO2011092655A2 (fr) Huile essentielle de mentha suaveolens et ses activités thérapeutiques
Saleem et al. Effect of cream containing Melia azedarach flowers on skin diseases in children
EP2061309B1 (fr) Compositions et procédés d'utilisation de celles-ci pour l'élimination de tiques de tissu épidermique
US6428823B1 (en) Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora persica L
Tchoumba Tchoumi et al. Antimicrobial and antidiarrhoeal activities of aqueous and methanolic extracts of Mangifera indica Linn stem bark (Anarcadiaceae) in Wistar rats
US20170020946A1 (en) Analgesic compositions and methods of use
Ebelle et al. Potentiating antifungal activity of fluconazole or nystatin with methanol bark extract of harungana madagascariensis stem bark
CN111248235A (zh) 一种可杀灭冠状病毒的中西药复配消毒/抑菌剂及制备方法
Ndeti et al. Efficacy of combination therapy using extracts of Aloe secundiflora Eng L and Callistemon citrinus William C. in Leishmania major infected BALB/c mice
KR102553206B1 (ko) 나노화된 벌화분 추출물을 유효성분으로 포함하는 여성청결제 조성물
Abuljadayel Antibacterial effect of extract from commiphora gileadensis; in vitro study

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120821

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20150303

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20171118